Akeso Reports Full-Year 2025 Financial Results [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
Commercial Operations Enter a New Phase of Growth In 2025, Akeso achieved record commercial sales revenue of RMB3,033.1 million , a year-on-year increase. All approved products and indications are now included in China's National Reimbursement Drug List (NRDL). The strong commercial growth in 2025 was fueled by strong clinical validation and widespread adoption by both healthcare professionals and patients By the end of 2025, several high-impact indications were added to the latest NRDL, including: Ivonescimab: 1L PD-L1(+) NSCLC Cadonilimab: 1L gastric cancer and 1L cervical cancer Other products: Multiple indications for penpulimab, ebdarokimab and ebronucimab With stable pricing for core first-line (1L) indications and improved hospital access, Akeso's commercial platform is positioned for a transformative 2026. Advanced Clinical Development of IO 2.0 Bispecifics Ivonescimab (PD-1/VEGF): As the world's first and only approved PD-1/VEGF bispecific antibody, ivonesc
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA Filing - What's Changed [Yahoo! Finance]Yahoo! Finance
- Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026Business Wire
- Summit Therapeutics (SMMT) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates [Yahoo! Finance]Yahoo! Finance
SMMT
Earnings
- 2/23/26 - Beat
SMMT
Sec Filings
- 2/23/26 - Form S-8
- 2/23/26 - Form 10-K
- 2/23/26 - Form 8-K
- SMMT's page on the SEC website